Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Next Previous
X
Search
Trial Profile

A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATG 101 (Primary)
  • Indications Adenocarcinoma; B-cell lymphoma; Colon cancer; Liver metastases; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms PROBE
  • Sponsors Antengene Corporation

    • Most Recent Events

    • 22 Mar 2024 According to an Antengene Corporation, completion of Phase I dose escalation and proceed to dose expansion in H1 2025.
    • 20 Mar 2024 According to an AEON Biopharma media release, the trial is currently in the sixth dose escalation cohort and the drug is approaching its biologically active dose with good tolerability
    • 08 Feb 2024 Planned number of patients changed from 482 to 40.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top